Memory Impairment - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
61 Pages - GMD12041
$2,000.00

Summary

Global Markets Direct’s, ‘Memory Impairment - Pipeline Review, H1 2014’, provides an overview of the Memory Impairment’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Memory Impairment
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Memory Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Memory Impairment pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Memory Impairment
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Memory Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Memory Impairment Overview 7
Therapeutics Development 8
Pipeline Products for Memory Impairment - Overview 8
Pipeline Products for Memory Impairment - Comparative Analysis 9
Memory Impairment - Therapeutics under Development by Companies 10
Memory Impairment - Therapeutics under Investigation by Universities/Institutes 12
Memory Impairment - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Memory Impairment - Products under Development by Companies 16
Memory Impairment - Products under Investigation by Universities/Institutes 17
Memory Impairment - Companies Involved in Therapeutics Development 18
F. Hoffmann-La Roche Ltd. 18
Suven Life Sciences Ltd. 19
M et P Pharma AG 20
Dart NeuroScience LLC 21
Omeros Corporation 22
Sunovion Pharmaceuticals Inc. 23
AbbVie Inc. 24
Memory Impairment - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 32
Assessment by Molecule Type 35
Drug Profiles 38
HT-1067 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
pregnenolone succinate - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
levetiracetam - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
HT-3951 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
2-PMPA - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
meldonium - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AC-253 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
RO-4938581 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SUN - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
A-582941 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SUVN-91121 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Antisense Oligonucleotide to Inhibit microRNA for Neurology - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules Targeting Galanin Receptor 3 for Memory Impairment and Depression - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules Targeting Phosphodiesterase 4 for Memory Impairment - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Drug to Activate Lipoprotein Lipase for Obesity and Brain disorders - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Adult Stem Cells - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Bryostatin Analogues - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Learning and Memory Program - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Drug for Memory Impairment - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Memory Impairment - Dormant Projects 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Number of Products under Development for Memory Impairment, H1 2014 8
Number of Products under Development for Memory Impairment - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Memory Impairment - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 18
Memory Impairment - Pipeline by Suven Life Sciences Ltd., H1 2014 19
Memory Impairment - Pipeline by M et P Pharma AG, H1 2014 20
Memory Impairment - Pipeline by Dart NeuroScience LLC, H1 2014 21
Memory Impairment - Pipeline by Omeros Corporation, H1 2014 22
Memory Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H1 2014 23
Memory Impairment - Pipeline by AbbVie Inc., H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Mechanism of Action, H1 2014 31
Number of Products by Stage and Route of Administration, H1 2014 34
Number of Products by Stage and Molecule Type, H1 2014 37
Memory Impairment - Dormant Projects, H1 2014 59

List of Figures
Number of Products under Development for Memory Impairment, H1 2014 8
Number of Products under Development for Memory Impairment - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 26
Number of Products by Stage and Top 10 Target, H1 2014 27
Number of Products by Top 10 Mechanism of Action, H1 2014 29
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 30
Number of Products by Top 10 Route of Administration, H1 2014 32
Number of Products by Stage and Top 10 Route of Administration, H1 2014 33
Number of Products by Top 10 Molecule Type, H1 2014 35
Number of Products by Stage and Top 10 Molecule Type, H1 2014 36

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax